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Abstract: Considerable debate surrounds the inclusion of schizoaffective disorder in psychiatric 
nosology. Schizoaffective disorder may be a variant of schizophrenia in which mood symptoms 
are unusually prominent but not unusual in type. This condition may instead reﬂ  ect a severe form 
of either major depressive or bipolar disorder in which episode-related psychotic symptoms fail 
to remit completely between mood episodes. Alternatively, schizoaffective disorder may reﬂ  ect 
the co-occurrence of two relatively common psychiatric illnesses, schizophrenia and a mood 
disorder (major depressive or bipolar disorder). Each of these formulations of schizoaffective 
disorder presents nosological challenges because the signs and symptoms of this condition 
cross conventional categorical diagnostic boundaries between psychotic disorders and mood 
disorders. The study, evaluation, and treatment of persons presently diagnosed with schizoaf-
fective may be more usefully informed by a dimensional approach. It is in this context that 
this article reviews and contrasts the categorical and dimensional approaches to its description, 
neurobiology, and treatment. Based on this review, an argument for the study and treatment of 
this condition using a dimensional approach is offered.
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Introduction
Schizoaffective disorder is characterized by persistent psychosis (eg, hallucinations, 
delusions) and mood episodes of depressive, manic, and/or mixed types. Although the 
DSM-based classiﬁ  cation of psychiatric disorders identiﬁ  es schizoaffective disorder 
as a speciﬁ  c clinical diagnosis, there remains a lack of consensus regarding both the 
conceptual and clinical aspects of this condition. It is possible that schizoaffective dis-
order simply reﬂ  ects the co-occurrence of two relatively common psychiatric illnesses, 
schizophrenia and a mood disorder (major depressive disorder or bipolar disorder), 
and therefore merits no unique identiﬁ  cation in psychiatric nosology. Alternatively, 
schizoaffective disorder may be a variant of schizophrenia in which mood symptoms 
(ie, sadness, euphoria, irritability) are more prominent and severe than usual but not 
inherently unusual in type. Conversely, this condition may reﬂ  ect severe forms of 
major depressive or bipolar disorders in which episode-related psychotic symptoms 
fail to remit completely between mood episodes (Marneros et al 1990, 1991; Dell’Osso 
et al 1993).
Such debates reﬂ  ect a categorical approach to the classiﬁ  cation of mental illness: 
in other words, an approach that requires the organization of clinical conditions 
into distinct categories (ie, Axis I vs Axis II, psychotic disorder vs mood disorder, 
schizophrenia vs schizoaffective disorder vs bipolar disorder, etc.). Although research 
efforts based on this approach require categorical distinctions between conditions 
under study, common clinical experience suggests that the psychiatric conditions 
with which many patients present do not conform completely, and sometimes not at 
all, to categorical diagnoses.Neuropsychiatric Disease and Treatment 2008:4(6) 1090
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An alternate approach to the study and treatment of 
psychiatric disturbances is to view psychiatric symptoms as 
disturbances within dimensions of neurobehavioral function. 
Perceptual processing and interpretation (ie, hallucinations 
and delusions) are dimensions of neurobehavioral function in 
which impairments are expressed to greater or lesser degrees 
among persons with a variety of neuropsychiatric conditions 
(Liddle et al 2006; Maier 2006). A dimensional approach to 
psychiatric diagnosis regards schizophrenia in its canonical 
form as a condition at the severely disordered end of the per-
ception and information interpretation continuum and at the 
normal end of the emotional regulation continuum, bipolar 
disorder as the converse of schizophrenia in these regards, 
and schizoaffective disorder as a condition reﬂ  ecting severe 
disturbances in all of these dimensions of neurobehavioral 
function.
Both categorical and dimensional approaches to the study 
and treatment of schizoaffective disorder are represented in 
the psychiatric literature, making difﬁ  cult the development of 
a clear clinical and neurobiological framework within which 
to consider this condition. In this article, we review clinical 
and neurobiological studies of schizoaffective disorder for 
the purpose of determining whether a categorical approach to 
psychiatric diagnosis provides a useful heuristic for the study 
and treatment of this condition. Evidence both supporting 
and challenging this approach is considered. Sources of data 
for this review were derived from a PubMed-based literature 
search, the criteria for which included ﬁ  rst all articles with 
the MeSH heading of schizoaffective disorder and then 
containing keywords relevant to the sections into which this 
article is organized: epidemiology, including incidence and 
prevalence, age of onset, gender, clinical presentation, and 
natural history; neurobiology, including neuropsychological 
ﬁ  ndings, neuroimaging, electrophysiology, neuroendocrine, 
neurochemical, and genetic features; and treatment. The 
section on treatment was limited to randomized controlled 
clinical trials (RCTs), metanalyses of clinical trials, and 
review articles in which schizoaffective disorder was a 
focus of treatment or in which persons with schizoaffective 
disorder represented a nontrivial number of study subjects. 
Where previously published reviews in reference textbooks 
or in the DSM-IV-TR sufﬁ  ced for the purposes of brevity, 
these sources were used and are cited.
Based on this review, we argue that a dimensional 
approach to the study and treatment of persons with persistent 
psychosis and episodic mood disturbances (ie, schizoaffective 
disorder in categorical diagnostic parlance) affords a more 
useful framework within which to study and treat persons 
with this condition. We argue further that neurogenetic 
studies will be particularly informative when a dimensional 
approach to the study and treatment of schizoaffective dis-
order is applied.
Historical considerations
The term “schizoaffective psychosis” was coined by Jacob 
Kasanin in 1933 (Kasanin 1994), who recognized in some 
patients the co-occurrence of symptoms suggesting both 
schizophrenia and mood (or, in the nosology of his era, 
“affective”) disorders. Kasanin described persons with this 
condition as experiencing relatively good pre-illness psy-
chosocial adjustment, an abrupt emotional presentation, less 
social withdrawal or passivity, a shorter course of illness, 
and relatively good recovery when compared to persons 
with schizophrenia. Consistent with this formulation, the 
ﬁ  rst (1952) and second (1968) editions of the Diagnostic 
and Statistical Manual of Mental Disorders (DSM) regarded 
schizoaffective disorder as a subtype of schizophrenia 
(see review in Wilson 1993). Although the fundamental 
concept of schizoaffective disorder as a psychotic disorder 
was maintained in DSM-III, this condition was separated 
from schizophrenia and instead assigned to the category 
“psychotic disorder not otherwise classiﬁ  ed.” Importantly, 
none of these classiﬁ  cation systems offered criteria speciﬁ  -
cally for schizoaffective disorder. During this time, some 
reports also began describing this condition as more similar 
to the mood disorders than to schizophrenia (Adler and 
Strakowski 2003; Strakowski et al 2003). Not surprisingly, 
more than 24 (ostensibly) different deﬁ  nitions of schizoaf-
fective disorder were developed in the years that followed 
(Winokur et al 1996).
The research diagnostic criteria (RDC) (Spitzer et al 
1978) made one of the ﬁ  rst attempts to distinguish schizoaf-
fective disorder from psychotic mood disorders; these criteria 
required not only the co-occurrence of psychotic and mood 
symptoms but also the persistence of psychotic symptoms for 
at least 1 week in the absence of prominent mood symptoms. 
Two diagnostic sub-groups were described on the basis of 
the quality of the most prominent types of mood symptoms: 
schizoaffective mania or schizoaffective depression. This 
left clinicians with the sometimes daunting task of deciding 
whether mood symptoms had resolved sufﬁ  ciently to merit 
a diagnosis of schizoaffective disorder or instead whether 
their persistence, even if in partial form, instead merited a 
diagnosis of an incompletely resolved psychotic mood dis-
order. This approach to the diagnosis of schizoaffective 
disorder permitted a liberal assignment of schizoaffective Neuropsychiatric Disease and Treatment 2008:4(6) 1091
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disorder where it met the research needs of investigators, 
and complicated the literature regarding this condition more 
than would application of stricter diagnostic criteria (Berner 
and Simhandl 1983).
An attempt to address this problem was made in the 
DSM-III-R (1987) (APA et al 1987), in which the diagno-
sis of schizoaffective disorder required the persistence of 
psychotic symptoms for at least two weeks beyond the reso-
lution of mood symptoms. Marneros and colleagues (1989a) 
further suggested that a diagnosis of schizoaffective disorder 
be assigned only when the mood symptoms are overtly mel-
ancholic or manic. The intent of that suggestion appears to 
have been to dissuade clinicians from assigning a schizoaf-
fective disorder diagnosis rather than schizophrenia solely 
on the basis of prominent but relatively minor depressive 
symptoms or euphoria. Beyond these reﬁ  nements, however, 
the diagnostic criteria for schizoaffective disorder offered in 
subsequent editions of the DSM remain largely unchanged 
(Frances et al 1995).
Phenomenonology 
of schizoaffective disorder
As noted in the preceding section, the DSM-IV-TR applies 
a categorical approach to the diagnosis of schizoaffective 
disorder, and then deﬁ  nes this condition according two the 
two major dimensions of neurobehavioral function it affects: 
thought (information processing) and mood (emotional 
regulation). The disturbance of thought must include two 
(or more) of the ‘A’ schizophrenia symptoms for a sig-
niﬁ  cant portion of time during a 1-month period (or less if 
successfully treated). The A symptoms include delusions, 
hallucinations, disorganized speech and grossly disorga-
nized or catatonic behavior. The mood disorder may include 
episodes that meet diagnostic criteria for a major depres-
sive episode (which must include depressed mood), manic 
episode, or mixed episode. The symptoms that meet criteria 
for a mood episode are present for a substantial portion of 
the total duration of the active and residual periods of the 
illness. As noted above, schizoaffective disorder is further 
divided into two subtypes based on the type of mood episodes 
with which the patient presents: bipolar or depressed. As an 
additional criterion, the DSM-IV states that during the period 
of illness there must be delusions or hallucinations for at 
least 2 weeks in the absence of prominent mood symptoms. 
Lastly, the symptoms meeting criteria for schizoaffective 
disorder may not be due to the direct physiological effects of 
a substance (eg, a drug of abuse, a medication) or a general 
medical condition.
In light of the substantial heterogeneity in the types of 
information processing and emotional regulation disturbances 
observed among persons with schizoaffective disorder, its 
status as a speciﬁ  c diagnostic category is dubious, at best. 
We suggest that it is simpler, and probably less confusing, to 
note ﬁ  rst that some patients experience clinically substantial 
disturbances in both of these domains of neurobehavioral 
function and to describe thereafter those disturbances care-
fully. This dimensional approach would avoid the categoriza-
tion of patients into mood disorders with psychotic features, 
schizophrenic disorders with minor mood disturbances, and 
schizoaffective disorder based on symptoms that are present 
at some point and to some degree in all of these conditions.
However, some authors have argued that subtle differ-
ences in clinical symptoms may distinguish between persons 
with schizoaffective disorder, schizophrenia, and bipolar 
disorder. For example, it has been reported that delusions 
at ﬁ  rst presentation are more frequent among persons with 
schizophrenia and schizoaffective disorder than among per-
sons with bipolar disorder, whereas hallucinations are more 
common among persons with schizophrenia than among 
those with schizoaffective or bipolar disorders (Whaley 
2002). Shenton and colleagues (1987) report that manic 
schizoaffective disorder patient tend to lack the humor and 
playfulness of manic bipolar patients, and are similar to 
schizophrenic patients in terms of idiosyncratic verbaliza-
tions, autistic thinking and confusion (Shenton et al 1987). By 
contrast, Pini and colleagues (2004) observed no differences 
in the frequency of speciﬁ  c types of delusions and hallucina-
tions between subjects with schizophrenia, schizoaffective 
disorder, psychotic mania and psychotic mixed mania, and 
argued that in clinical practice such subtle distinctions in 
clinical symptoms rarely clarify diagnosis along categorical 
boundaries (Pini et al 2004). Again, the lack of clear and 
consistent phenomenological distinctions between these 
conditions argues against the usefulness of a categorical 
diagnostic approach to schizoaffective disorder.
In fact, persons with schizoaffective disorder (as well as 
schizophrenia and psychotic mood disorders) often expe-
rience dysfunction in other neurobehavioral domains of 
function. In a psychiatric nosology that relies on categorical 
distinctions, dysfunction in other neurobehavioral domains 
may require the assignment of additional clinical diagnoses. 
For example, Byerly and colleagues (2004, 2005) observed 
that of 100 men with a diagnosis of schizophrenia or schizoaf-
fective disorder, 30% have obsessive-compulsive symp-
toms. Strauss and colleagues (2006) found that in 165 male 
patients with schizophrenia or schizoaffective disorder nearly Neuropsychiatric Disease and Treatment 2008:4(6) 1092
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50% experienced symptoms consistent with a diagnosis of 
posttraumatic stress disorder (PTSD), and that the presence 
of such symptoms was associated with a higher risk of 
suicidality. These observations are useful in that they identify 
other neurobehavioral dimensions (eg, stereotypies or ritual-
istic behaviors in the case of obsessive-compulsive disorder 
and anxiety and/or trauma-related symptoms in the case 
of PTSD) that also may be affected by the neurobiological 
process producing the phenomenology schizoaffective 
disorder. However, when the presence of such symptoms 
entails the assignment of additional diagnoses, as is the case 
in a categorical diagnostic nosology, it violates the rule of 
parsimony: if obsessive-compulsive symptomatology is pres-
ent in nearly a third of persons with schizoaffective disorder 
and posttraumatic stress disorder symptoms are present in 
nearly half of persons with schizophrenia and schizoaffec-
tive disorder, the utility of identifying such symptoms by 
diagnoses separate from the primary clinical condition with 
which the patient presents (ie, schizoaffective disorder) is 
questionable. Alternatively, and perhaps more usefully, such 
observations may suggest the propensity of the underlying 




Differences in the natural history of schizophrenia, bipolar 
disorder, and schizoaffective disorder are among the fea-
tures often purported to facilitate distinctions between 
these conditions. However, the lack of diagnostic reliability 
and stability – particularly in the case of schizoaffective 
disorder – presents a serious challenge to such arguments. 
For example, Maj and colleagues (2000) independently inter-
viewed 150 patients using two psychiatrist diagnosticians and 
reviewed reliability for individual elements of the DSM-IV 
criteria for schizoaffective and mood disorder diagnosis. 
They report lower inter-rater reliability scores for schizoaf-
fective disorder when compared with those for manic and 
depressive diagnoses. Vollmer-Larsen and colleagues (2006) 
re-evaluated hospital records and discharge summaries of 
59 patients with hospital discharge diagnoses of schizoaf-
fective disorder and found that using an operational criteria 
checklist, none of the patients fulﬁ  lled lifetime diagnostic 
criteria for schizoaffective disorder and only six patients 
met possible ICD-10 criteria for schizoaffective disorder. 
They argued for a moratorium on the use of schizoaffective 
disorder as a psychiatric diagnosis on the basis of its poor 
stability over time.
Similarly, Schwartz and colleagues (2000) report 
relatively high stability of diagnosis at re-evaluation 6- and 
24-months later among persons with schizophrenia (92%), 
bipolar disorder (83%), and major depression (74%), and 
relatively poor stability of diagnosis among persons with 
psychosis not otherwise speciﬁ  ed (44%), schizoaffective 
disorder (36%), and brief psychotic disorder (27%). In cases 
where diagnostic reassignment at 24-months was required, 
the most frequent shift was to a schizophrenia-spectrum 
disorder. A similar point is made by Whaley (2002) in a ret-
rospective case review investigating the presenting features 
schizoaffective disorder at initial evaluation and the effect 
of those features on diagnosis. They observed that patients 
whose index episode is depressive are more likely to receive 
a bipolar diagnosis whereas those whose index episode is 
manic are more likely to receive a diagnosis of schizoaffec-
tive or a bipolar disorder. In other words, the clinical features 
of the presenting episode inﬂ  uence assignment of diagnosis 
despite the absence of the longitudinal data required to make 
substantiate such diagnoses.
The relative lack of stability and reliability of diagnosis 
inﬂ  uence other elements of schizoaffective disorder, includ-
ing ascertainment of outcome and prognosis. Some studies 
suggest that the symptomatic and long-term function of per-
sons with schizoaffective disorder is similar to that associated 
with schizophrenia (Tsuang and Coryell 1993; Harrow et al 
2000; Benabarre et al 2001). Other studies suggest a better 
symptomatic and functional outcome of schizoaffective 
disorder when compared to schizophrenia and an outcome 
similar to that of mood disorders (Marneros et al 1989b; 
Tohen et al 2000). Still others suggest that the outcome of 
persons with schizoaffective disorder is better than that of 
those with schizophrenia but worse than those with mood 
disorders (Benabarre et al 2001; del Rio Vega and Ayuso-
Gutierrez 1990, 1992).
These often contradictory observations leave entirely 
uncertain the natural history of schizoaffective disorder. 
Given that schizoaffective disorder reﬂ  ects the occurrence 
of variable degrees of dysfunction along dimensions of neu-
robehavioral function prominently disturbed in schizophrenia 
and also in mood disorders, it is not surprising that such 
contradictions in ascertainment of outcome are observed. 
Variations in the dimensions of neurobehavioral function 
emphasized in the assignment of a schizoaffective disorder 
diagnosis (ie, information processing, emotional regulation, 
or both) would predictably vary in the manner in which they 
compare to patients whose illness reﬂ  ect relatively “pure” 
disturbances in only one of these dimensions. As suggested Neuropsychiatric Disease and Treatment 2008:4(6) 1093
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by Vollmer-Larsen and colleagues (2006), a categorical 
diagnosis of schizoaffective disorder will produce problems in 
the study of outcomes among persons assigned this diagnosis. 
By contrast, a dimensional approach – one that emphasizes 
the type and severity of disturbances in speciﬁ  c domains of 
neurobehavioral function – may permit a more useful tracking 
of outcome, particularly as regard to the effects of dysfunction 
in information processing and emotional regulation on the 
ability of patients to meet the challenges of everyday life.
Epidemiology
Incidence and prevalence
Although the DSM-IV-TR states without citation that the 
prevalence of schizoaffective disorder is less than of schizo-
phrenia, there are at present few data on which to base ﬁ  rm 
estimates of the prevalence of schizoaffective disorder. 
Scully (2004) and Marneros (2003) offer data suggesting 
that the lifetime prevalence of schizoaffective disorder ranges 
between 0.2%–1.1% (Zarate et al 1997; Marneros 2003; 
Scully et al 2004) report a higher frequency (9%) of schizoaf-
fective disorder among hospitalized psychiatric inpatients. 
In a more recent Spanish study of 138 outpatients, nearly 
identical rates of schizoaffective disorder and schizophrenia 
are reported; each of which was slightly half as common as 
bipolar disorder (type I) (Benabarre et al 2001).
Schizoaffective disorder appears to be rare among 
psychotic children (Werry et al 1991). The diagnosis of 
schizoaffective disorder among younger persons may be 
more challenging than among adults. Relative difﬁ  culty arriv-
ing at this diagnosis may be a function of greater uncertainty 
compared with adults regarding symptoms and diagnostic 
stability over time (McClellan and McCurry 1999; Hollis 
2000). In addition, co-morbidity of intellectual disabilities 
(Friedlander and Donnelly 2004) and potential issues with 
substances of abuse and/or medications in this age range 
(Malla et al 2000) may complicate the diagnosis and conse-
quently identify the incidence and prevalence.
The limited literature on prevalence and incidence sug-
gests that schizoaffective disorder, at its most frequent, is 
as prevalent as schizophrenia and less common than bipolar 
disorder. When diagnostic stability is entered into estimates 
regarding the prevalence of schizoaffective disorder, it 
appears that schizoaffective disorder is less common than 
bipolar disorder or schizophrenia. As noted in the preced-
ing sections of this article, the wide range of estimates 
of prevalence of schizoaffective disorder should prompt 
concerns regarding the methods by which this diagnosis is 
ascertained. In studies emphasizing disturbances along the 
information processing dimension, the estimated prevalence 
of schizoaffective disorder would be expected to be similar 
to that of schizophrenia but less than that of bipolar disorder. 
Conversely, if severe disturbances along both information 
processing and emotional regulation are emphasized in 
categorical diagnosis, then schizoaffective disorder would 
be expected to be less common than both schizophrenia 
and bipolar disorder. Co-morbidity of schizophrenia and 
bipolar disorder appears to yield estimates of the prevalence 
of schizoaffective disorder reported to date: if co-morbidity 
explained the diagnosis of schizoaffective disorder, then its 
prevalence should be the product of that for schizophrenia 
multiplied by that of bipolar disorder with psychosis and/or 
psychotic depression (ie, a very low prevalence, and one 
much lower than that of any of these conditions alone). 
Given the variability in the extent to which disturbances in 
these dimensions of neurobehavioral function are consid-
ered relevant to categorical diagnosis, similar variability 
is prevalence estimates seems unavoidable. If, however, 
a dimensional approach to the evaluation and treatment of 
persons with neurobehavioral disturbances is used then such 
variability becomes less relevant; the focus of concern would 
then become identifying the frequency with which such dis-
turbances occur regardless of “diagnosis” and whether such 
disturbances are functionally relevant.
Age of onset
Schizoaffective disorder appears to have a broad age of 
onset in adults (del Rio Vega and Ayuso-Gutierrez 1990). 
Marneros and colleagues (1990) prospectively interviewed 
and reviewed records of approximately 900 people with 
either schizophrenia, mood disorders, or schizoaffective 
disorder (Marneros et al 1990). Approximately one third 
of patients with schizoaffective disorder developed the 
condition between ages 25 and 35, one third developed the 
condition prior to age 25 (similar to the mean age of onset 
for schizophrenia in this study) and one third developed the 
condition after age 35 (simarly to the mean age of onset for 
bipolar disorder in this study). Angst and Preisig (1995) 
observed earlier ages of onset among adults with schizoaffec-
tive disorder unipolar and bipolar subtypes than among adults 
with “pure” unipolar and bipolar mood disorders (Angst and 
Preisig 1995). Similarly, Dell’Osso and colleagues (1993) 
observed a younger age of onset among adult subjects with 
schizoaffective disorder than among subjects whose illness 
was characterized by either psychotic mania or psychotic 
mixed mood episodes (Dell’Osso et al 1993). Although 
pediatric onset of schizoaffective disorder is uncommon, the Neuropsychiatric Disease and Treatment 2008:4(6) 1094
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age at which this illness ﬁ  rst occurs does not appear to differ 
from that of either pediatric-onset schizophrenia or bipolar 
disorder (approximately 14 years) (Werry et al 1991).
The available evidence suggests that the age of onset 
range for adult schizoaffective disorder spans the age of onset 
of bipolar disorder and schizophrenia and the median age is 
between the median age of schizophrenia and bipolar dis-
order. Such variability would be expected if schizoaffective 
disorder if is understood as variant of either bipolar disorder 
or schizophrenia, a co-occurrence of these two conditions, 
or instead a distinct clinical condition. If schizoaffective 
disorder represents a co-occurrence of two distinct diagnoses 
(schizophrenia and a mood disorder), then the age of onset of 
schizoaffective disorder should be identical to schizophrenia: 
the ﬁ  rst-onset of symptoms meeting diagnostic criteria for 
schizophrenia should not differ between these conditions. If 
instead age of onset is a variant of bipolar disorder in which 
there is persistence of psychotic symptoms between mood 
episodes, then age of onset of schizoaffective disorder should 
be similar to that of the mood disorder of which it is a variant 
(ie, bipolar or major depressive disorder).
That both of these scenarios explain age of onset in approx-
imately one-third of cases each and fails to explain age of onset 
in the remaining third of cases suggests, at a minimum, that 
these methods of establishing the onset of schizoaffective dis-
order is problematic. By contrast, if categorical diagnoses are 
abandoned in favor of a dimensional approach to identifying 
functionally signiﬁ  cant disturbances in information processing 
and mood, then the need to even make comparisons between 
ages of onset across diagnostic categories is unnecessary. 
Instead, it would sufﬁ  ce as a starting point in clinical practice 
to note that the onset of clinically important disturbances in 
information processing tends to antedate the onset of function-
ally signiﬁ  cant disturbances in emotional regulation. Regard-
less of the domain in which neurobehavioral disturbances arise 
initially, however, vigilance for disturbances in the other is 
maintained and measures designed to prevent and/or treat 
disturbances in both domains are undertaken.
Gender
The DSM-IV-TR states without reference that schizoaffec-
tive disorder probably occurs more often in women. This is 
consistent with Marneros and colleagues (1990b) report that 
two-thirds of persons with schizoaffective disorder are female, 
an observation echoed by other studies (Angst et al 1980; 
Marneros et al 1990; Lenz et al 1991). If clinically signiﬁ  cant 
disturbances in emotional regulation are more common among 
women, then it should not be surprising that schizoaffective 
disorder occurs more frequently in women (Cohen 2003). 
As in previous sections, it might be more useful if clinicians 
remained vigilant for clinically signiﬁ  cant disturbances in 
emotional regulation among women with information pro-
cessing deﬁ  cits (ie, psychotic symptoms) in the service of 
proactively preventing or treating such problems rather than 
focusing instead on categorical diagnostic reassignment.
Neurobiology 
of schizoaffective disorder
It is reasonably well accepted that the clinical phenomena used 
to characterize schizophrenia, mood disorders, and schizoaf-
fective disorder are manifestations of disturbances in multiple 
domains of neurobiological function. These disturbances are 
amenable to study using neuropsychological, neuroimaging, 
electrophysiologic, neurochemical, and genetic investigations. 
Studies investigating the neurobiology of schizoaffective 
disorder separate from that of schizophrenia or mood (usually 
bipolar) disorders are few; instead, most include subjects with 
schizoaffective disorder among those with either schizophre-
nia or bipolar disorder. At ﬁ  rst glance, the tendency to include 
persons with schizoaffective disorder in one of these two 
groups would appear to bespeak some measure of agreement 
among researchers regarding the difﬁ  culty of clearly distin-
guishing between persons with schizoaffective disorder and 
these other conditions on the basis of their neurobiological fea-
tures. While this remains a possibility, it is also noteworthy that 
most investigations focus on only one or a few neurobiological 
disturbances that reﬂ  ect a speciﬁ  c domain of neurobehavioral 
function, usually either information processing (manifesting 
as psychosis or related cognitive impairments) or emotional 
regulation but not both. In effect, studies investigating the 
neurobiology of schizoaffective disorder use a dimensional 
approach to study-group assignment.
With this in mind, the following sections review the 
neurobiology of schizoaffective disorder as revealed by 
the inclusion of persons in study groups with dysfunction 
in information processing, emotional regulation, or both. It 
will become clear that when information processing, by any 
method, is the focus of study then persons with schizoaffec-
tive disorder are neurobiologically indistinguishable from 
those developing similar information processing deﬁ  cits 
in any psychiatric diagnostic context (ie, schizophrenia 
or psychotic mood, and particularly bipolar, disorders). 
By contrast, when emotional regulation is the focus of study 
then persons with schizoaffective disorder are indistinguish-
able neurobiologically from those with mood disorders. 
Implications of these findings on future investigations Neuropsychiatric Disease and Treatment 2008:4(6) 1095
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regarding the characterization and treatment of persons with 
schizoaffective disorder will be summarized after presenting 
the data supporting this argument.
Neuropsychological testing
Much like schizophrenia, schizoaffective disorder is 
associated with impairments in frontally-mediated cognition, 
including working memory, alternating attention, information 
recall, category generation, abstraction, and motor planning 
(Table 1; Kolakowska et al 1985; Oltmanns et al 1985; 
Mitrushina et al 1996; Bryson et al 1997; Manschreck 
et al 1997; Bryson et al 2002; Gooding and Tallent 2002; 
Brenner et al 2003; Woodward et al 2004; Goldstein 
et al 2005; Stip et al 2005; Glahn et al 2006; Nangle et al 
2006; Pope and Kern 2006; Roofeh et al 2006). In only 
two studies was it noted that schizoaffective disorder was 
associated with better neuropsychological performance 
on such tests than persons with schizophrenia (Goldstein 
et al 2005; Stip et al 2005). However, in this ﬁ  rst of these 
studies, the differences were few and suggested only that 
Table 1 Neuropsychological studies of persons with schizoaffective disorder
Reference Population Measures Findings
Bryson et al 1997 SCZ = 55 
SAD = 8
WCST, WAIS-R, Hopkins Verbal 
Learning, Gorham’s Proverbs, CPT
Greater severity of mood symptoms was 
associated with perseverative errors, fewer 
complete categories on WCST and a 
greater number of errors on CPT.
Woodward et al 2004 SCZ = 62 
SAD = 6
RAVLT, BVMT, SSPI In a combined group of SAD and SCZ 
patients, an association was found between 
psychomotor poverty and deﬁ  cit of episodic 
memory.
Glahn et al 2006 SCZ = 15 
SAD = 15 
BMD = 26 
Controls = 32
WAIS, DRT Patients with BMD, SCZ and SAD had 
deﬁ  cits on backward digit span. Patients 
with a lifetime history of psychosis had 
impairment in spatial delayed response task.
Gooding et al 2002 SCZ = 24 
SAD = 12 
Controls = 29
Nonverbal working memory SCZ and SAD patients performed poorly 
on working memory tasks that are based on 
the identity and/or features of the stimulus 
(ie, object-based working memory tasks) as 
well as on a working memory task based on 
the spatial location of the stimulus.
Gooding et al 2002 SCZ = 34 
SAD = 23 
Controls = 30
Spatial working memory and WCST Both SAD and SCZ had deﬁ  cits which 
differed from controls but not each other.
Nangle et al 2006 SCZ = 50 SAD = 18 WAIS, CPT,   WTAR, WMS 1/3 of patients were classiﬁ  ed as suicide 
attempters and 2/3 as nonattempters in an 
Irish Population. SCZ and SAD patients who 
are attempters outperformed nonattempters 
in attention and verbal ﬂ  uency.
Goldstein et al 2005 SCZ = 63 
SAD = 20 
Controls = 21
WAIS and Trails Cognitive function of SAD and paranoid 
subset of SCZ subjects were more 
cognitively intact than subjects with 
undifferentiated and residual types of SCZ.
Manschreck et al 1997 SCZ = 19 
SAD = 19 
MDD = 19 
Controls = 19
Verbal recall with alteration of context SCZ subjects attain smaller gains in recall 
when context is increased compared to 
depressed and normal controls. SCZ and 
SAD subjects, however, did not differ in 
recall gain on this task.
Roofeh et al 2006 SCZ = 37 
SAD = 20 
Controls = 60
CVLT SAD and SCZ did not differ. Schizophrenic 
spectrum was worse than age and 
gender matched controls on measures 
of apprehension, verbal learning, short-
term memory, long-term memory and 
organizational strategies.
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subjects with schizophrenia experienced greater deﬁ  cits 
in posteriorly-mediated (ie, visuospatial) cognitive func-
tions than persons with schizoaffective disorder (Stip et al 
2005). Findings from the second of these studies may offer 
clariﬁ  cation on this observation: persons with schizoaffec-
tive disorder and paranoid schizophrenia were cognitively 
indistinguishable, but both groups differed cognitively from 
persons with undifferentiated and residual schizophrenia 
subtypes (Goldstein et al 2005). The authors argued that 
schizophrenia itself is a heterogeneous diagnosis; accord-
ingly, subtyping of schizophrenia groups on the basis of 
the presence or absence of disturbances in other domains 
or severities of neurobehavioral dysfunction may result in 
separation between these clinical subgroups. Collectively, 
these observations suggest that when information processing 
(cognition) is the focus of study, persons with schizoaf-
fective disorder are in most regards similar to those with 
schizophrenia.
Structural neuroimaging (computerized 
tomography and magnetic resonance 
imaging)
The neuroimaging literature of schizoaffective disorder 
is predominated by structural magnetic resonance imag-
ing (MRI) studies, although diffusion tensor imaging, 
functional MRI, and magnetic resonance spectroscopy are 
emerging as additional methods of investigation (Table 2; 
Jurjus et al 1993; Cannon et al 1998; Bilder et al 1999; 
Table 1 (Continued)
Reference Population Measures Findings
Brenner et al 2003 SCZ = 31 
SAD = 11
Visual discrimination and recognition, 
and tests of abstraction, verbal learning, 
visual memory, working memory and 
attention WCST, CVLT, CPT, and Family 
Pictures
Seven subjects with SCZ or SAD were 
impaired on Family Pictures ﬁ  rst recall. 
Eight were impaired on Letter Number 
Sequencing. WCST performance was 
impaired in 12 subjects. CVLT performance 
was impaired in 28 subjects. CPT 
performance was impaired in nine subjects.
Bryson et al 2002 SAD = 14 
SCZ = 28
WCST,   WAIS SCZ and SAD patients were below normal 
at initial assessment. Reassessment 3 years 
later did not show a decrease in function, 
and 20% showed some improvement.
Mitrushina et al 1996 SCZ = 21 
SAD = 18 
BMD I = 18 
MDD with Psychosis = 25 
Psychotic DO NOS = 25
Neurobehavioral Cognitive Status 
Examination
SAD and SCZ had a deﬁ  cit on “similarities’ 
scale suggesting a deﬁ  cit in abstract 
reasoning. SAD and SCZ also had a deﬁ  cit 
in terms of lowest spontaneous recall.
Oltmanns et al 1985 SCZ = 10 
BMD I = 11 
SAD = 11 
MDD = 10
Ratings of verbal communication 
impairments
SAD, SCZ and BMD subjects had more 
derailment than normals and MDDs. SAD, 
BMD and SCZ all had loss of goal and 
decreased global rating compared with 
normals and MDDs.
Pope and Kern 2006 SCZ and SAD = 36 
Controls = 22
Word-stem completion task A measure of learning was applied to this 
combined population of SCZ and SAD. 
The combined group had more problems 
with the task when errors where included 
in the task.
Stip et al 2005 SAD = 13 
SCZ = 44
Motor Screening, reaction time, Paired 
Associates Learning Task, and Stockings 
of CANTAB items
SCZ and SAD differed on visuo-motor 
coordination and visuospatial substests, 
with SAD subjects performing better than 
subjects with SCZ.
Kolakowska et al 1985 SCZ = 42 
SAD = 14
Neurological 'soft' signs, CT scan 
and cognitive impairment
No relationship between the size of the 
lateral brain ventricles on CT scan and 
either ‘soft' signs or cognitive impairment.
Abbreviations: SAD, schizoaffective disorder;  SCZ, schizophrenia; BMD I, type I bipolar mood disorder;  MDD, major depressive disorder;  CVLT, California Verbal Learning Test; 
DRT, Spatial Delayed Response Task;    WCST,   Wisconsin Card Sort Test; CPT, Continuous Performance Task;   WAIS, Wechsler Adult Intelligence Test;   WMS, Wechsler Memory 
Scale;   WTAR, Wechsler Test of Adult Reading; RAVLT, Rey Auditory Verbal Learning Test; BVMT, Brief Visual Memory Test; SSPI, Signs and Symptoms of Psychotic Illness; CT, 
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Table 2 Neuroimaging ﬁ  ndings among studies of persons with schizoaffective disorder
Reference Population Method Findings
Jurjus et al 1993 SCZ = 67
BMD and SAD = 60
Controls = 37
cMRI A higher frequency of cavum septum pellucidum was observed 
among subjects with SCZ than among BMD and SAD subjects. No 
clinical difference was found between SCZ with or without cavum 
septum pellucidum.
Prasad et al 2004 SCZ and SAD = 33
Non-SCZ psychotic 
disorders =11 Controls = 43
vMRI Left parahippocampal gyrus (PHG) was signiﬁ  cantly smaller in subjects 
with SCZ compared to non-SCZ psychotics but not controls. In 
psychotic subjects, PHG volume negatively correlated with total 
positive symptom, delusion and conceptual disorganization scores. 
Patients with delusions had relatively smaller PHG compared to 
nondelusional subjects.
Buchanan et al 2004 SCZ and SAD = 44
Controls = 34
vMRI Patients had smaller inferior prefrontal region volumes and reversal 
of the normal asymmetry of the inferior parietal cortex. No 
signiﬁ  cant group differences were found in superior temporal gyrus 
volume.
Van Erp et al 2004 Probands with SAD = 12
SCZ = 60 Proband siblings = 58 
Controls = 53
vMRI Decrease hippocampal volumes in probands compared to siblings. 
Decrease volumes of siblings compared to normal controls. SAD 
probands have diminshed hippocampal volumes with fetal hypoxia. 
Decreased hippocampal volumes correlate positively with age at 
onset for the combined SCZ and SAD group.
Canon et al 2002 SCZ and SAD = 64
1st degree relatives = 51 
Controls = 54
vMRI Fetal hypoxia predicted reduced gray matter and increased CSF
bilaterally throughout the cortex in patients and siblings, most 
strongly in the temporal lobe. Hypoxia correlated signiﬁ  cantly with 
ventricular enlargement, but only among subjects with psychosis.
Getz et al 2002 SAD = 12
BMD = 12 Controls = 12
vMRI SAD and BMD had signiﬁ  cantly smaller cerebral volumes than 
controls. Globus pallidal difference was the largest contribution 
to this difference.
Bilder et al 1999 Mood DO and SAD = 81
SCZ and SCZF = 87
Controls = 67
vMRI A composite index of asymmetry across regions ('torque'), all 
showed the same diagnostic group effect, with the SCZ group 
showing least normal asymmetry, the mood DO group intermediate 
asymmetry, and the control group the most asymmetry.
Cannon et al 1998 SCZ = 62
SAD = 12 
Nonpsychotic siblings = 60 
Controls = 56
vMRI Subjects with SCZ and SAD and their siblings exhibited signiﬁ  cant 
reductions in cortical gray matter volume and signiﬁ  cant increases 
in sulcal CSF volume compared with controls. The subjects, but not 
their siblings, exhibited signiﬁ  cant reductions in white matter volume 
and signiﬁ  cant increases in ventricular CSF volume. For subject and 
sibling groups, gray matter volume reductions and sulcal CSF volume 
increases were signiﬁ  cantly most pronounced in the frontal and 
temporal lobes.
Szeszko et al 2005 First episode SAD = 5
SCZ = 5 Controls = 13
MRI-DTI Decrease left internal capsule and left-hemisphere white matter 
of middle frontal gyrus and posterior superior temporal gyrus.
Ardekani et al 2003 SCZ and SAD = 14
Controls = 14
MRI-DTI Abnormal white matter in corpus callosum, left superior temporal 
gyrus, parahippocampal gyri, middle temporal gyri, inferior parietal 
gyri, medial occipital lobe, and deep frontal perigenual region.
Stone et al 2005 SCZ = 6
SAD = 2
All subjects with memory 
deﬁ  cits
fMRI Greater activation of the left parahippocampus in the glucose 
condition, compared to the saccharin condition, despite no change 
in memory performance.
Keshavan et al 2003 SAD = 10
SCZ = 6
Controls = 37
P31 MRS Increase in psychotic subjects of freely mobile phosphomonoester 
which is consistent with white matter changes in this group of 
patients.
Abbreviations: SAD, schizoaffective disorder; SCZ, schizophrenia; BMD, bipolar mood disorder; Mood DO, mood disorder; SCZF, schizophreniform; cMRI, conventional 
magnetic resonance imaging; vMRI, volumetric magnetic resonance imaging; MRI-DTI, magnetic resonance imaging with diffusion tensor imaging; fMRI, functional magnetic 
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Cannon et al 2002; Getz et al 2002; Ardekani et al 2003; 
Keshavan et al 2003; Buchanan et al 2004; Prasad et al 2004; 
Van Erp et al 2004; Stone et al 2005; Szeszko et al 2005). In 
general, these studies have found that schizoaffective disorder 
is associated with reductions in cerebral volumes, particularly 
temporal (including medial temporal) and frontal regions, 
including both gray and white matter. The most consistent 
areas of abnormality across these studies are the hippocampus 
and parahippocampal gyri. Subjects with schizoaffective 
disorder are generally found to be similar to the other diag-
nostic group in which they are included (ie, schizophrenia 
or bipolar disorder) and different from healthy comparison 
subjects; when comparisons are made between schizophrenia 
and schizoaffective disorder, few differences are evident. 
These observations echo our earlier suggestion that the focus 
of the neurobehavioral dimension under study (information 
processing or emotional regulation) tends to predict both 
similarities and differences between subjects with schizoaf-
fective disorder, schizophrenia, and mood disorders.
Electrophysiology
Schizoaffective disorder is associated with abnormal event-
related potentials (P50, N100, N400, CNV, and others), 
localization of sensory evoked magnetic ﬁ  elds, middle ear 
muscle activity, and eye movements (Table 3; Benson and 
Zarcone 1982; Goode and Manning 1985; Saccuzzo and 
Braff 1986; Borenstein et al 1988; Lieberman et al 1993b; 
Keshaven et al 1995; Benson et al 1996; Boutros et al 1997; 
Bruder et al 1998; Inui et al 1998; Reite et al 1999; Kayser 
et al 1999, 2001; Teale et al 2000; Brenner et al 2003; 
Kathmann et al 2003; Kumar and Debruille 2004; Olincy and 
Martin 2005). Subjects with schizoaffective disorder were 
primarily contrasted with subjects with either schizophrenia 
or bipolar disorder with psychotic features. Boutros and 
colleagues (1997) and Inui and colleagues (1998) published 
studies which suggest more similarity between schizoaffec-
tive disorder and bipolar disorder with psychotic features than 
with schizophrenia. As with other categories in this review 
the strength of the literature limits the conclusions we can 
make regarding the electrophysiological distinction between 
these conditions. However, these studies do suggest that 
psychosis (ie, information processing impairment), regard-
less of categorical psychiatric diagnosis and its expression as 
persistent or mood-episode-related, is associated with elec-
trophysiologic abnormalities. This observation also argues 
for a dimensional approach to the study of electrophysiologic 
indices of information processing abnormalities rather than 
a categorical diagnostic approach.
Neuroendocrine function
There are only three studies to-date, all of which evaluated 
differences in growth hormone levels, that evaluate neu-
rohormonal changes in schizoaffective disorder (Table 4; 
Kumar et al 1993; Lieberman et al 1993b; Mokrani et al 
2000). Mokrani and colleagues (2000) studied growth hor-
mone responses to clonidine challenge among subjects with 
schizoaffective disorder, schizophrenia, and major depressive 
disorder. They observed similar responses between subjects 
with schizophrenia and healthy comparison subjects and 
similar responses between schizoaffective subjects and those 
with major depressive disorder. By contrast, Kumar and 
colleagues (1993) and Lieberman and colleagues (1993a) 
demonstrated similarities in growth hormone response to 
pharmacologic treatment in patients with psychosis and 
emotional regulation disturbances regardless of categorical 
psychiatric diagnosis. Although this literature is not devel-
oped sufﬁ  ciently to permit ﬁ  rm conclusions, it appears that 
neuroendocrine disturbances are more closely related to 
dysfunction in either the information processing domain, 
emotional regulation domain, or both, than to categorical 
diagnosis. One would predict that other neuroendocrine 
abnormalities, and particularly those assessing the hypotha-
lamic – pituitary – adrenal axis, might be more closely related 
to disturbances in emotional regulation than to information 
processing abnormalities. As reiterated below, focusing 
future investigations along dimensional lines might facilitate 
identiﬁ  cation of neuroendocrine abnormalities than does a 
categorical diagnostic approach.
Neurochemical function
Studies of neurotransmitter function that include persons 
with schizoaffective disorder are few, and consist primarily 
of observational studies of cerebrospinal ﬂ  uid (CSF) or 
serum neurotransmitter metabolites. In an earlier review, 
Meltzer and colleagues (1984) reported similar patterns of 
neurochemical abnormalities among persons with schizo-
phrenia, bipolar disorder, and schizoaffective disorder. 
In that review, it was reported that CSF norepinephrine, 
prostaglandin E1, norepinephrine and PGE1 adenyl cyclase 
and platelet 5HT levels among persons with schizophrenia 
and schizoaffective disorder are similar, while platelet 5HT 
proﬁ  les are more alike among persons with bipolar disorder 
and schizoaffective disorder than those with schizophrenia. 
Subsequent studies of these sorts (Table 5; Laruelle et al 
1993; Sharma et al 1993, 1994, 1995, 1997, 1998; Faustman 
et al 1999) have generally observed no differences between 
persons with these conditions; instead, neurotransmitter Neuropsychiatric Disease and Treatment 2008:4(6) 1099
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Table 3 Electrophyiologic studies of persons with schizoaffective disorder
Reference Population Method Findings
Olincy and 
Martin 2005
BMD = 42 
SAD = 22 
Controls = 42
ERPs P50 auditory 
evoked potential
SAD and BMD with psychosis demon-
strated higher P50 ratios (nonsuppres-
sion) compared to controls and BMD 
subjects without a history of psychosis.
Kumar and 
Debruille 2004
SCZ and SAD Review of 10 studies of N400 
amplitude in these populations
Diminished N400 amplitude in SCZ 
and SAD.
Brenner et al 2003 SCZ and SAD = 23
Controls = 22
ERPs sensory N100 and EEG 
synchronization to modulated 
auditory tones
SCZ and SAD have decreased power in 
steady-state responses to periodic stimuli, 
despite normal N100 responses.
Kayser et al 2001 SCZ = 46
SAD = 20 
Controls = 32
ERPs tonal and oddball tasks Patients showed marked, task-independent 
reductions of early negative potentials. 
Task-related hemispheric asymmetries 
were similar in healthy adults and subjects.
Kayser et al 1999 SCZ = 16
SAD = 8
Controls = 19
ERPs of a continuous word 
recognition memory task
Accuracy of word recognition memory 
was poorer in subjects than controls, and 
subjects showed markedly smaller N2 
amplitude. Among controls, asymmetry 
was not present in patients and suggested 
a left lateralized deﬁ  cit among subjects.
Bruder et al 1998 SCZ = 19
SAD = 9
Controls = 28
ERPs during a dot 
enumeration task
Subjects showed poorer dot enumeration 
than did controls and also had markedly 
reduced early negative ERPs.








SAD had signiﬁ  cant decrease in P200 
compared with controls and SCZ (but 
not BMD) and otherwise did not separate 
from other groups.
Borenstein et al 1988 SCZ = 27
SAD = 13 
Controls = 27
ERPs – CNV 
(contingent negative variation)
Pre- and post-imperative phases of 
the CNV were heterogeneous in 
character suggesting the possibility of 
multiple disturbances. When present, 
the pre-imperative negativity was of 
lower amplitude and had a delayed return 







ERPs – visual masking paradigm 
assessing response at 500 msec 
post-stimulus
MDD was different than SAD, BMD and 
SCZ in some measures of this paradigm.
Inui et al 1998 SCZ = 33
SAD = 12
Mood-incongruent 
psychotic mood disorder = 12 
nonpsychotic mood disorder = 62
SCZF = 12
EEG Increased epileptiform variants in 
mood-incongruent psychotic mood 
disorder (33%), SAD (33%), and SCZF
(30%), compared with nonpsychotic 
mood disorder (3.2%) and SCZ (0%).
Benson et al 1996 SAD = 3
SCZ = 11
EEG and CT measures of 
ventricular volume
Deﬁ  cits in slow wave sleep correlated 
with ventricular volume
Keshaven et al 1995 SCZ = 12
SAD = 8
EEG – slow-wave delta sleep Decreased percentage of delta sleep 
signiﬁ  cantly correlated with poorer 
clinical outcomes at 1 and at 2 years.




MDD = 10 
Controls 13
Rate of middle ear muscle 
activity during REM sleep
Middle ear muscle activity was lowest 
for SAD, than normal patients, than 
depressed and highest for SCZ patients.
Teale et al 2000 SCZ = 14 
SAD = 12 
Controls = 23
MEG – Localization of 
magnetic sources for auditory 
M100 signals
SAD and SDZ exhibited different source 
localization in auditory cortex compared 
to one another and controls.
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Table 3 (Continued)
Reference Population Method Findings
Reite et al 1999 SAD = 16 
Controls = 16
Magnetoencephalography 
(MEG) M20 for median nerve 
stimulation
Reversed asymmetry of M20 in SAD 
located on the post-central gyrus in this 
disorder.
Kathmann et al 2003 SCZ and SAD = 54
Affective DO = 43
Relatives: Psychosis = 43 
Affective DO = 36
Controls = 84
Eye tracking tasks Decreased eye pursuit gain in SCZ and 
affective disorders. This deﬁ  cit is present, 
to a lesser extent, in their relatives.
Lieberman 1993 SAD = 16
SCZ = 54
Eye movement tracking Morphologic abnormalities of the medial 
temporal lobe and third ventricle were 
associated with normal eye tracking 
suggesting changes in SAD and SCZ are 




SAD = 10 EMG – Hoffmann reﬂ  ex 
recovery
Right-left differences in Hoffmann reﬂ  ex 
(H reﬂ  ex) recovery curve height signiﬁ  -
cantly correlated with standardized scales 
of psychopathology.
Abbreviations: SAD, schizoaffective disorder; SCZ, schizophrenia; BMD, bipolar mood disorder; Mood DO, mood disorder; MDD, major depressive disorder; SCZF, 
schizophreniform; ERP, event-related potential; EEG, electroencephalography; CT, computed tomography; REM, rapid eye movement; MEG, magnetoencephalography; EMG, 
electromyography.
abnormalities are more strongly associated with symptom 
severity (and particularly psychosis) as well as outcome 
measures (ie, length of hospitalization). Again, a dimensional 
approach to the study of these populations appears to inform 
more usefully on cerebral neurochemical abnormalities than 
categorical psychiatric diagnosis.
Genetics
There have been few studies performed with the intent 
of identifying genetic differences between persons with 
schizoaffective disorder and other major psychiatric dis-
orders. Instead, most studies have grouped subjects with 
schizoaffective disorder among those with either schizo-
phrenia or bipolar disorder depending on the dimension of 
neurobehavioral dysfunction (ie, information processing 
or emotional regulation) emphasized by the investigators 
(Table 6; Weiss et al 1996; Cardno et al 2001; Ujike et al 
2001; Dick et al 2003; Segurado et al 2003; Skol et al 2003; 
Wijsman et al 2003; Willour et al 2003; Giouzeli et al 2004; 
Hodgkinson et al 2004; Kirov et al 2004; Hamshere et al 
2005; Liu et al 2005; Staddon et al 2005; DeLisi et al 2002; 
Faraone et al 2002). As with other types of neurobiological 
investigations, these studies have generally failed to distin-
guish schizoaffective disorder from either schizophrenia or 
bipolar disorder on the basis of their genetic underpinnings. 
Hodgkinson and colleagues (2004) report that schizoaffective 
disorder, has an underrepresentation of a common haplotype 
from the intron 1/exon 2 region of DISC1 (on chromosome 
1q42), as well as overrepresentation of the DISC1 exon 
9 missense allele Phe607. The potential importance of this 
particular abnormality of DISC1 follows from the need to 
identify a mechanism by which dysfunction in both the 
information processing and emotional regulation dimensions 
of neurobehavioral function are produced (Hodgkinson et al 
2004; Ishizuka et al 2006; Porteous et al 2006).
DISC1 (an acronym for Disrupted-In-Schizophrenia-1) 
appears to play a role in neurodevelopment and is preferen-
tially expressed in the forebrain. Posttranslational modiﬁ  ca-
tion produce multiple isoforms of this protein. DISC1 protein 
is expressed in multiple intracellular compartments, including 
the nucleus, centrosome, mitochondria, microtubule frac-
tions, actin cytoskeletal fractions, and postsynaptic densities, 
Among the possible functions of DISC1, mediation of centro-
some-dynein cascade and cyclic adenosine monophosphate 
(cAMP) signaling have been described. DISC1 also interacts 
with other proteins that may mediate neurobehavioral func-
tion, including Ndel1 and PDE4B. The former regulates 
neuronal migration via endo-oligopeptidase activity, and the 
latter is a phosphodiesterase involved in cyclic adenosine 
monophosphate signaling. PDE4B is of particular interest 
in that it is linked to both information processing (memory) 
and emotional regulation.
Abnormalities of DISC1 are regarded as potential genetic 
risk factors for both schizophrenia and bipolar disorder Neuropsychiatric Disease and Treatment 2008:4(6) 1101
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Table 4 Neuroendocrine studies of persons with schizoaffective disorder
Reference Population Method Findings
Mokrani et al 2000 SAD = 31 
SCZ = 16 
MDD = 87 
Controls = 22
Growth hormone 
responses to the 
clonidine challenge
Lower GH response to stimulation with 
clonidine among MDD and SAD subjects 
when compared to SCZ subjects and 
controls.
Kumar and Marks 1993 Post-partum and 
a history of BMD or SAD
SCZ = 46 




responses to clonidine and 
apomorphine challenge
Increased growth hormone response to 
apomorphine challenge test compared to 
those who remained well and to controls. 
Life events history did not inﬂ  uence these 
ﬁ  ndings.
Lieberman et al 1993 SAD = 16 
SCZ = 54
Controls = 50
GH secretion in response 
to methyphenidate 
challenge
Abnormal GH secretion and decreased 
GH response to methylphenidate in the 
subjects with psychosis.
Abbreviations: SAD, schizoaffective disorder; SCZ, schizophrenia; BMD, bipolar mood disorder; MDD, major depressive disorder; MDE, major depressive episode; 
GH, growth hormone.
Table 5 Neurochemical studies of persons with schizoaffective disorder
Reference Population Method Findings




CSF glutamate Ratings of positive symptoms were inversely correlated 
with CSF glutamate concentrations. Hallucinatory 
behavior was strongly correlated with CSF glutamate 
concentrations. In a subset of subjects who received 
haloperidol, haloperidol did not alter CSF glutamate 
concentrations and symptoms no longer correlated 
with CSF glutamate levels.
Sharma et al 1998 Inpatients with: 
SCZ = 33
SAD = 21
Plasma HVA Correlation between length of inpatient stay and 
plasma HVA levels.
Sharma et al 1993 Inpatients with: 
SCZ = 15
SAD = 4
CSF – HVA Plasma homovanillic acid levels correlated with length 
of inpatient treatment but not other measures or 
group differences.
Sharma et al 1997 Inpatients with: 
SCZ = 29
SAD = 13
CSF neurotensin Neurotensin levels were decreased pre-treatment in 
both SAD and SCZ subjects. Lower neurotensin levels 
pre-treatment were associated with increased severity 
of psychopathology. Neurotensin levels increased with 
treatment.
Sharma et al 1995 SAD, SCZ, BMD 
(either manic or 
depressed) = 16
CSF phenylacetic acid No difference in CSF phenylacetic acid levels 
as a function of psychiatric diagnosis.
Sharma et al 1994 Inpatients with: 
SAD = 3
SCZ = 14
CSF somatostatin Duration of treatment correlated with CSF 
somatostatin levels, but there were no differences 
between subject groups.
Laruelle et al 1993 SCZ = 12
SAD = 9 
Nonpsychotic 




Serotonin uptake sites were decreased in prefrontal 
cortex of psychotic subjects who died of natural causes, 
but not among psychotics who died from suicide, 
controls, and nonpsychotic suicide victims.
Abbreviations: SAD, schizoaffective disorder; SCZ, schizophrenia; BMD, bipolar mood disorder; HVA, homovanillic acid; 5-HT, serotonin; PGE1, prostaglandin E1 stimulated 
adenylate cyclase activity; NE, norepinephrine; GABA, gamma-aminobutyric acid.Neuropsychiatric Disease and Treatment 2008:4(6) 1102
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Table 6 Genetic studies of persons with schizoaffective disorder
Reference Population Genetic linkage Ethnicity/Geography
Hamshere et al 2005 SAD = 35 Suggestive linkage on chromosomes 
1q42, 22q11,19p13.
United Kingdom
Liu et al 2005 SCZ and SAD = 52 Suggestive linkage of neuregulin 1 (NRG1) 
on chromosome 8p21 (NRG1 is an isoform 
of glial growth factor 2).
Taiwanese family
Staddon et al 2005 SCZ = 105
SAD = 13
Controls = 162
Increase in dopamine D3 receptor gene 
alleles-7685-C, SeaGly and 205 G/A.
Basque family
Giouzeli et al 2004 SCZ and SAD = 294 Families 
containing 2 members with 
these diagnoses
Neither the coding variants nor the intron 
polymorphisms of protocadherin X/Y are 
related to psychosis within families.
United Kingdom




SAD has decrease of the common haplotype 
of intron 1/exon 2 of DISC1. In addition, 
SAD has an increase in exon 9. Multiple 
haplotypes between exon 1 and 9 are associ-
ated with SCZ, SAD and BMD. (DISC1 gene, 
on chromosome 1q42, was discovered and 
linked to schizophrenia in a Scottish kindred 
carrying a translocation).
United States
Kirov et al 2004 Parents of probands with:
SCZ = 441
SAD =47
Increase in DTNBP1 markers 
p1635 and p 1757.
Bulgaria
Skol et al 2003 SCZ =361
SAD = 31
Increase in NOTCH4 at 6p21.3. United States veterans
Willour et al 2003 BMD I = 134
BMD II = 41
SAD = 5
MDD = 43
Large predominant bipolar pedigree 
had linkages at 4q35, 4q 32 and 20p12.
United States 
BMD pedigrees
Dick et al 2003 BMD I = 232
SAD/Bipolar type = 32 
BMD II = 72 MDD = 88, 
recurrent and siblings.
Large predominant bipolar pedigree with 
linkage greatest at 17q, 6q, and less at 2p, 
3q and 8q. The less strong linkages included 
patients with less severe BMD and MDD.
United States
Segurado et al 2003 BMD = 2300 cases, 
617 pedigrees and spectrum
SAD/Bipolar = 82
Findings were not signiﬁ  cant 
on 13q or 22q.
Ireland
Wijsman et al 2003 SCZ and SAD = 32 Linkage at 2q37 in a population 
of reduced heterogeneity.
Micronesia
Faraone et al 2002 Family members of subjects with:
SCZ = 360
SAD = 32
Linkage at 13q32. United States veterans
DeLisi et al 2002 SCZ and SAD = 294 Families 
containing at least 2 members 
with these diagnoses
Linkage on chromosome 5q. Costa Rica
Cardno et al 2001 Sibling pairs with either SCZ 
or SAD. Total = 94
Six areas of possible relationship 
of age of onset of schizophrenia 
to speciﬁ  c 20 cM areas of DNA in 13q
United Kingdom
Ujike et al 2001 SCZ = 188
SAD = 3
Controls = 143
NOTCH4 at 6p21.3 not signiﬁ  cant in Japan. Japan 
Weiss et al 1996 SCZ = 91
SAD = 20
MDD/dysthymia = 90
Increase in frequency of D4.7 allele and 
DRD4 polymorphism in patients with 
psychosis.
Germany
Abbreviations: SAD, schizoaffective disorder; SCZ, schizophrenia; BMD, bipolar mood disorder; BMD I, type I bipolar mood disorder; BMD II, type II bipolar mood disorder; 
MDD, major depressive disorder; DNA, deoxyribonucleic acid.Neuropsychiatric Disease and Treatment 2008:4(6) 1103
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(Ishizuka et al 2006). The findings of Hodgkinson and 
colleagues (2004) suggest the possiblility that particular 
abnormalities of this gene, or the manner in which its prod-
uct undergoes posttranslational modiﬁ  cation, may produce 
dysfunction in both information processing and emotional 
regulation. In some cases, these disturbances may affect 
information processing more so than emotional regulation 
(producing the phenotype of schizophrenia with minor mood 
disturbances), in others the emotional regulation dimension 
may be more severely affected (bipolar disorder), or severe 
disturbances in both of these neurobehavioral domains (ie, 
schizoaffective disorder). It is unlikely that disturbances in 
DISC1 are the only, or perhaps even the primary, genetic 
basis for the severe multidimensional neurobehavioral 
dysfunction observed among persons presently identiﬁ  ed 
with schizoaffective disorder rather than schizophrenia or 
bipolar disorder. However, such data suggest the possibility 
that the neurobiological bases of information processing and 
emotional regulation may have distinct genetic contributions 
that in some cases may be linked (as by speciﬁ  c abnormalities 
of DISC1) and thereby produce severe problems in both of 
these neurobehavioral domains. If this thesis is correct, it sug-
gests that the categorical approach to psychiatric diagnosis 
will ultimately fail as a useful psychiatric nosology and that 
a dimensional approach, perhaps predicated on the genetics 
of speciﬁ  c neurobehavioral domains, to the study and treat-
ment of persons with neurobehavioral disorders will prove 
more productive.
Treatment
Although inferential reasoning regarding diagnosis and 
neurobiology from pharmacologic treatment studies is 
ill-advised, it is noteworthy that treatment approaches to 
schizoaffective disorder echo the dimensional approach 
suggested here. Despite the identiﬁ  cation of schizoaffec-
tive disorder as a distinct diagnosis in the DSM-based 
system, there are no treatments speciﬁ  c for this condi-
tion. Instead, symptom-guided treatment approaches are 
generally advocated for persons with this conditions. 
Table 7 (Keck et al 1996; Levinson et al 1999; McElroy 
et al 1999; Vieta et al 2001; Tohen et al 2001; Bilder et al 
2002; Sajatovic et al 2002; Chengappa et al 2003; Harvey 
et al 2003, 2004; Marder et al 2003; Baethge et al 2004; 
Davis and Chen 2004) summarizes a sample of treatment 
studies in which patients with schizoaffective disorder are 
included; Few of these publications emphasize the treatment 
of schizoaffective disorder alone, and where this disorder 
is the focus of study it appears that symptom proﬁ  le along 
dimensional lines (information processing vs emotional 
regulation vs both), rather than subtype of this diagnosis, 
determines treatment recommendations.
Conclusion
The challenge of describing schizoaffective disorder within 
a psychiatric nosology that requires categorical distinctions 
between diagnostic entities is substantial. Using a categori-
cal diagnostic approach, the data reviewed herein suggests 
that schizoaffective disorder can be argued with nearly 
equal merit to be a variant of either schizophrenia or a mood 
(and particularly bipolar) disorder, a condition in which 
schizophrenia and a mood disorder are co-morbid, or a unique 
psychiatric disorder. This conclusion, however unsatisfy-
ing, appears to be unavoidable if a categorical approach to 
psychiatric diagnosis is undertaken. Moreover, the present 
review suggests that the challenges schizoaffective disorder 
presents to categorical psychiatric diagnosis are not unique 
to this condition, but are instead pervasive in psychiatric 
research and practice. Although most studies begin with the 
premise that schizophrenia and bipolar disorder are distinct 
conditions, the observation of minor mood disturbances 
among persons with the former and often severe psychosis 
among those with the latter should raise concerns about the 
certainty of clear diagnostic boundaries between them. The 
consistent observation of neuroimaging, electrophysiologic, 
neurochemical, neuroendocrine, genetic, and treatment ﬁ  nd-
ings that more effectively follow psychiatric symptoms rather 
than categorical diagnoses suggests that the former, and not 
the latter, may be the more useful focus of both psychiatric 
research and clinical practice.
Indeed, the present review suggests that the study, 
evaluation, and treatment of persons with psychiatric dis-
order is likely to be most productive when anchored to the 
dimensions of neurobehavioral dysfunction with which they 
present. This approach, which derives from the approach 
used in behavioral neurology and neuropsychiatry, begins 
with the premise that cognition, emotion, behavior, and 
sensorimotor function are distinct but interrelated domains 
of neurobehavioral function (Arciniegas and Kaufer 2006). 
Regardless of the clinical condition (eg, stroke, trauma, 
neurodegenerative disease, idiopathic psychiatric illness) 
producing disturbances in these neurobehavioral domains, it 
is posited that their neuroanatomic and neurochemical bases 
are likely to be similar despite differences in the conditions 
disturbing brain structure and function. It is further sug-
gested that there may be etiology-speciﬁ  c neuroanatomic, 
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condition producing neurobehavioral disturbances that are 
potential modiﬁ  ers of their expression, persistence, and/or 
treatment-response. While bearing these modiﬁ  ers in mind, 
the study, evaluation, and treatment of persons with neu-
robehavioral disturbances is then organized according to 
the dimension(s) of neurobehavioral function in which such 
disturbances are expressed.
It is our assertion that this approach is particularly 
well-applied to the study, evaluation, and treatment of 
schizoaffective disorder. This condition reﬂ  ects aberrations 
in the distributed neural networks serving both information 
processing (ie, perception, information interpretation) and 
emotional regulation, among other possible dimensions 
of disordered neurobehavioral function, in persons whose 
presentations are currently described as ‘schizoaffective’. 
It is conceivable that other factors, including genetic and 
epigenetic variations and environmental contributors, may 
inﬂ  uence the expression of disturbances in information 
processing and emotional regulation domains, and that such 
factors may weigh particularly heavily on one rather than the 
other. In such circumstances, the presentation would be one 
that appears to be predominated by either psychotic or mood 
disturbances rather than by both. Directing the study, evalu-
ation, and treatment at the core disturbances in information 
processing and/or emotional regulation, regardless of how 
these disturbances direct assignment of categorical psychi-
atric disorder, it is likely that a more coherent description 
of the relevant neurobiology and effective treatments would 
emerge. By extension, application of this neuropsychiatric 
approach to other psychiatric disorders may facilitate their 
study, evaluation, and treatment and also avoid the vagaries 
entailed by a psychiatric nosology predicated on categorical, 
and ultimately arbitrary, diagnoses.
Disclosure
Dr Rojas receives support from MH60214.
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